Insider · CIK 0001595989

Ono Richard Dana

Reports to the SEC for 2 companies · SALT LAKE CITY, UT

sec.gov

Transactions

Companies

Filings

CIK

0001595989

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-03	LPCNLipocine Inc. · Common Stock (Right to Buy)A Award	Director	AAward	+1,764 sh	$2.19	+$3,863.16	13,290
2025-06-04	LPCNLipocine Inc. · Common Stock (Right to Buy)A Award	Director	AAward	+1,764 sh	$3.20	+$5,644.8	11,526
2024-06-05	LPCNLipocine Inc. · Common Stock (Right to Buy)A Award	Director	AAward	+1,764 sh	$7.05	+$12.4K	10,938
2023-05-10	LPCNLipocine Inc. · Common Stock (Right to Buy)A Award	Director	AAward	+30K sh	$0.27	+$7,968	166,000
2023-03-20	LPCNLipocine Inc.P Purchase	Director	PPurchase	+4,000 sh	$0.34	+$1,360	14,125
2022-06-08	LPCNLipocine Inc. · Common Stock (Right to Buy)A Award	Director	AAward	+22K sh	$0.92	+$20.2K	136,000
2021-06-09	LPCNLipocine Inc. · Common Stock (Right to Buy)A Award	Director	AAward	+22K sh	$1.26	+$27.7K	22,000
2020-12-22	INTIInhibitor Therapeutics, Inc. · Common Stock OptionA Award	Director	AAward	+755K sh	—	—	754,839
2020-12-16	LPCNLipocine Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,250 sh	—	—	10,125
2020-12-16	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	+5,250 sh	—	—	5,250
2020-06-10	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	$0.96	+$21.2K	22,000
2020-03-20	INTIInhibitor Therapeutics, Inc. · Common Stock OptionA Award	Director	AAward	+1M sh	—	—	1,000,000
2019-06-12	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	$1.68	+$16.8K	10,000
2019-02-03	INTIInhibitor Therapeutics, Inc. · Common Stock OptionA Award	Director	AAward	+658K sh	—	—	657,895
2018-06-27	LPCNLipocine Inc. · Stcck Optoin (right to buy)A Award	Director	AAward	+20K sh	$1.33	+$26.6K	20,000
2018-03-13	INTIInhibitor Therapeutics, Inc. · Common Stock OptionA Award	Director	AAward	+253K sh	—	—	253,000
2018-03-13	INTIInhibitor Therapeutics, Inc. · Common Stock OptionA Award	Director	AAward	+56K sh	—	—	56,000
2017-12-29	LPCNLipocine Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,750 sh	—	—	5,750
2017-12-29	LPCNLipocine Inc.S Sale	Director	SSale	−875 sh	$3.47	−$3,033.362	4,875
2017-12-29	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−1,750 sh	—	—	5,250
2017-03-08	INTIInhibitor Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+300K sh	—	—	300,000
2017-03-08	INTIInhibitor Therapeutics, Inc.F Tax Payment	Director	FTax Payment	−119K sh	$0.34	−$40.4K	181,200
2017-03-08	INTIInhibitor Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+300K sh	—	—	481,200
2017-03-08	INTIInhibitor Therapeutics, Inc.F Tax Payment	Director	FTax Payment	−119K sh	$0.34	−$40.4K	362,400
2017-03-08	INTIInhibitor Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+150K sh	—	—	512,400
2017-03-08	INTIInhibitor Therapeutics, Inc.F Tax Payment	Director	FTax Payment	−59.4K sh	$0.34	−$20.2K	453,000
2017-03-08	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−300K sh	—	—	0
2017-03-08	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−300K sh	—	—	0
2017-03-08	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−150K sh	—	—	0
2017-01-26	LPCNLipocine Inc. · Restricted Stock UnitA Award	Director	AAward	+7,000 sh	—	—	7,000
2016-07-01	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+150K sh	—	—	150,000
2016-07-01	INTIInhibitor Therapeutics, Inc. · Options to Purchase Common StockA Award	Director	AAward	+150K sh	—	—	150,000
2016-06-14	LPCNLipocine Inc. · Common Stock (right to buy)A Award	Director	AAward	+10K sh	$8.02	+$80.2K	10,000
2015-08-14	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+300K sh	—	—	300,000
2015-06-16	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	30,000
2014-11-19	LPCNLipocine Inc.P Purchase	Director	PPurchase	+4,000 sh	$5.14	+$20.6K	4,000
2014-07-18	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+300K sh	—	—	300,000
2014-01-06	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000

Recent filings

Accepted (ET)
Jun 44
Ono Richard Dana0001493152-26-027259
SEC(opens sec.gov)
Jun 54
Ono Richard Dana0001641172-25-013796
SEC(opens sec.gov)
Jun 74
Ono Richard Dana0001493152-24-023213
SEC(opens sec.gov)
May 124
Ono Richard Dana0001493152-23-016690
SEC(opens sec.gov)
Mar 204
Ono Richard Dana0001493152-23-008304
SEC(opens sec.gov)
Jun 104
Ono Richard Dana0001493152-22-016406
SEC(opens sec.gov)
Jun 104
Ono Richard Dana0001638599-21-000539
SEC(opens sec.gov)
Dec 284
Ono Richard Dana0000899243-20-035201
SEC(opens sec.gov)
Dec 174
Ono Richard Dana0001638599-20-000980
SEC(opens sec.gov)
Jun 104
Ono Richard Dana0001638599-20-000591
SEC(opens sec.gov)
Mar 244
Ono Richard Dana0000899243-20-009312
SEC(opens sec.gov)
Jun 144
Ono Richard Dana0001638599-19-000609
SEC(opens sec.gov)
Feb 54
Ono Richard Dana0000899243-19-002715
SEC(opens sec.gov)
Jun 284
Ono Richard Dana0001638599-18-000699
SEC(opens sec.gov)
Mar 154
Ono Richard Dana0000899243-18-007587
SEC(opens sec.gov)
Jan 24
Ono Richard Dana0001638599-18-000026
SEC(opens sec.gov)

Companies

Address

C/O 675 ARAPEEN DR SUITE 202

SALT LAKE CITY, UT, 84108